288 related articles for article (PubMed ID: 27935735)
1. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler LA; Alperin S; Leon T; Faraone SV
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):196-199. PubMed ID: 27935735
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
4. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Findling RL; Wu J; Kollins SH; Wang Y; Martin P; Robertson B
J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):128-136. PubMed ID: 32233956
[No Abstract] [Full Text] [Related]
5. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.
Ermer JC; Pennick M; Frick G
Clin Drug Investig; 2016 May; 36(5):341-56. PubMed ID: 27021968
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Babcock T; Dirks B; Adeyi B; Scheckner B
BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
[TBL] [Abstract][Full Text] [Related]
8. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
Ermer J; Corcoran M; Lasseter K; Martin PT
Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
Coghill DR; Banaschewski T; Lecendreux M; Zuddas A; Dittmann RW; Otero IH; Civil R; Bloomfield R; Squires LA
Eur Child Adolesc Psychiatry; 2014 Feb; 23(2):61-8. PubMed ID: 23708466
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
Martin PT; Corcoran M; Zhang P; Katic A
Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
Adler LA; Alperin S; Leon T; Faraone S
Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD.
Adler LA; Lynch LR; Shaw DM; Wallace SP; O'Donnell KE; Ciranni MA; Briggie AM; Faraone SV
J Atten Disord; 2017 Jan; 21(2):149-157. PubMed ID: 23657761
[TBL] [Abstract][Full Text] [Related]
16. ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years.
López FA; Childress A; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser RA; Shepski J; Arnold V
J Atten Disord; 2017 Jan; 21(1):52-61. PubMed ID: 23407278
[TBL] [Abstract][Full Text] [Related]
17. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults.
Mattingly G
CNS Spectr; 2010 May; 15(5):315-25. PubMed ID: 20448522
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
[TBL] [Abstract][Full Text] [Related]
20. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]